This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Salix Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Salix Pharmaceuticals, Ltd. (SLXP)

Q2 2012 Earnings Call

August 8, 2012 5:00 pm ET


Michael Freeman – Associate Vice President, Investor Relations and Corporate Communications

Adam C. Derbyshire – Chief Financial Officer, Executive Vice President-Finance and Administration

Carolyn J. Logan – President and Chief Executive Officer

William P. Forbes – Executive Vice President-Research and Development and Chief Development Officer


Michael Faerm – Credit Suisse

Ami Fadia – UBS Securities LLC

Mario Corso – Caris & Co., Inc.

David A. Amsellem – Piper Jaffray, Inc.

Corey Davis – Jeffries & Co, Inc.

Jim Dawson – Buckingham Research

Annabel Samimy – Stifel, Nicolaus & Co., Inc.

Irina Rivkind – Cantor Fitzgerald Securities

Michael Tong – Wells Fargo Securities LLC

Andrew J. Finkelstein – Susquehanna Financial Group LLP

Liisa A. Bayko – JMP Securities LLC

Scott R. Henry – ROTH Capital Partners LLC

Patricia Banks – DISCERN Securities, Inc.

Gregory D. Fraser – Bank of America/Merrill Lynch



Good afternoon. My name is Jay, and I will be your conference operator today. At this time, I would like to welcome everyone to Salix Pharmaceuticals’ Second Quarter 2012 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. (Operator Instructions) Thank you.

Mr. Michael Freeman, Associate Vice President of Investor Relations, you may begin.

Michael Freeman

Thank you. Good afternoon, and thank you for joining us today. I am Mike Freeman, Associate Vice President of Investor Relations and Corporate Communications for Salix Pharmaceuticals. With me today are Carolyn Logan, President and Chief Executive Officer; Adam Derbyshire, Executive Vice President and Chief Financial Officer; and Bill Forbes, Executive Vice President, Medical and Research and Development, and Chief Development Officer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs